Prognosis
UK Signs BioNTech Deal to Treat 10,000 With Custom Cancer Drugs
- Patients will be able to participate as early as September
- Deal may be worth $750 million over 8-10 years, person says
This article is for subscribers only.
The UK government agreed to work with BioNTech SE to treat as many as 10,000 cancer patients with personalized therapies by 2030, a research partnership that will give the German company quicker access to patients it needs to test its drugs.
The collaboration could be worth as much as $750 million over the next eight to 10 years, a person familiar with the matter said. UK patients will be able to participate in the program as early as September, Health and Social Care Secretary Steve Barclay said in a statement.